Recombinant Therapeutic Antibodies and Proteins Market, by Drug Class (Plasma Protein, Growth factors, Fusion Proteins, Monoclonal Antibodies, Hormones, Enzyme, Coagulation Factors, and Others), by Application (Oncology, Hematology, Immunology, Endocrinology, Infectious Disease, Cardiovascular Disease, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, trends, and Forecast to 2026

  • Published On : Jul 2018 |
  • Pages : 160 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Recombinant Therapeutic Antibodies and Proteins Market– A Novel Approach to Treat Rare and Chronic Diseases

Therapeutic proteins are engineered in the laboratory for pharmaceutical use, including non-covalent binders. These proteins are highly effective and serve as modernized treatment for rare as well as chronic diseases. Protein therapeutics offer custom-made treatment approach by supporting a specifically targeted therapeutic process by compensating the deficiency of an essential protein. Recombinant proteins have gained significant traction for therapeutic applications and the number of proteins either launched or approved into clinical trials has continually increased over the past two decades. According to the National Center for Biotechnology Information (NCBI) data of 2017, the U.S. Food and Drug Administration (FDA) approved over 140 recombinant therapeutic proteins for human use and several hundred are currently in development. Majority of these proteins are recombinant monoclonal antibodies.

The global recombinant therapeutic antibodies and proteins market size was valued at US$ 91.2 billion in 2017, and is expected to witness a robust CAGR of 12.2% over the forecast period (2018 – 2026).

Figure 1. Global Recombinant Therapeutic Antibodies and Proteins Market Share (%), By Drug Class

   

Source: Coherent Market Insights Analysis (2018)

 

Advancements in recombinant therapeutic drugs are expected to bolster the recombinant therapeutic antibodies and proteins market growth

Integration of novel approaches and strategies to modify protein drug products is an important aspect. Advancements in recombinant protein technologies have allowed drug manufacturers and developers to adjust required functional characteristics of proteins of interest while maintaining product efficacy and safety.

Various recombinant technologies are currently in use to increase the half-life, functionality, and targeting of novel therapeutic protein drugs and increase product purity and volume. For instance, protein conjugation and derivatization methods, including albumin-fusion15, PEGylation and Fc-fusion are currently being used to extend a drug’s circulating half-life.

Monoclonal antibodies (mAbs) are most commonly used recombinant therapeutic products. The production of most monoclonal antibody products is easily amenable to effective platform-based approaches as antibodies are highly specific and the risk of unexpected safety issues in human clinical trials of mAb products is less as compared to other types of therapeutic products. The constant evaluation of monoclonal antibody drugs in new and expanded clinical indications results in constant demand for products in clinical studies ensuing increased sales in newly approved indications.

Figure 2. Recombinant Therapeutic Antibodies and Proteins Market (US$ Bn), By Region, 2017

Source: Coherent Market Insights Analysis (2018)

Increasing government support for novel drug development is expected to augment the market growth

Governments are supporting research and development of novel products due to rapid advancements in biomedical science and technology to address unmet medical needs. In 2012, the Food and Drug Administration Safety and Innovation Act (FDASIA) was signed to provide the FDA with the capability to establish breakthrough therapy designation (BTD), a new program within the Expedited Programs for Serious Conditions. It was designed to be available for drugs designed to treat a serious condition and that have been shown to exhibit initial clinical evidence of significant improvement over existing treatments.

Moreover, increasing number of rare diseases significantly impacting public health is expected to drive growth of the recombinant therapeutic antibodies and proteins market size. According to National institute of Health (NIH) 2018 report, an estimated 7,000 different disorders collectively affect about 10% of the U.S. population, mainly young children and many lack effective treatments. In order to encourage the development of drugs that specifically address unmet medical needs, in 2013, an orphan designation was given for drugs used for the treatment of less than 200,000 patients in the U.S.

However, government regulations are stringent for production and approval of recombinant therapeutic drugs in order to ensure that these products are effective and safe.

Major players operating in the global recombinant therapeutic antibodies and proteins market include Abbott, Amgen Inc., Biogen Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Johnson and Johnson, Merck & Co., Novo Nordisk, Pfizer Inc., and Sanofi S.A.

Recombinant therapeutic protein drugs are an important class of medicines, which helps patients in need of novel therapies. Recently approved recombinant protein therapeutics have been developed to treat a wide variety of clinical indications, including cancers, inflammation/autoimmunity, genetic disorders, and exposure to infectious agents. The latest advancements in protein-engineering technologies have allowed drug manufacturers and developers to adjust desirable functional characteristics of proteins of interest maintaining product efficacy. Protein-based therapies are highly successful and experience unparalleled growth potential in terms of their efficacy.

Market Dynamics

Recombinant therapeutic proteins and antibodies have gained high traction in clinical applications. Due to development of antibody-based therapeutics, mammalian expression systems have experienced a major boost and microbial expression systems continue to be widely used in industries, which in turn will fuel growth of the market. However, variations in production methods of therapeutic antibodies can lead to differences in their structure, based on the selection of recombinant procedure. Most protein therapeutics available in the market are recombinant and majority of them are in clinical trials for therapy of immune disorders, cancers, infections, and other diseases. Various engineered proteins, including multi-specific fusion proteins, bi-specific monoclonal antibodies (mAbs) and mAbs conjugated small molecule drugs, and proteins with optimized pharmacokinetics are under development.

Key features of the study:

  • This report provides in-depth analysis of recombinant therapeutic antibodies and proteins market and provides market size (US$ Million) and cumulative annual growth rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global recombinant therapeutic antibodies and proteins market based on the following parameters – company overview, financial performance, product portfolio, market presence, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Abbott, Amgen Inc., Biogen Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Johnson and Johnson, Merck & Co., Novo Nordisk, Pfizer Inc., and Sanofi S.A.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global recombinant therapeutic antibodies and proteins market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the recombinant therapeutic antibodies and proteins market

Detailed Segmentation:

  • Global Recombinant Therapeutic Antibodies and Proteins Market, By Drug Class:
    • Plasma Protein
    • Growth Factors
    • Fusion Proteins
    • Monoclonal Antibodies
    • Hormones
    • Enzyme
    • Coagulation Factors
    • Others
  • Global Recombinant Therapeutic Antibodies and Proteins Market, By Application:
    • Oncology
    • Hematology
    • Immunology
    • Endocrinology
    • Infectious Disease
    • Cardiovascular Diseases
    • Others
  • Global Recombinant Therapeutic Antibodies and Proteins Market, By Geography:
    • North America Recombinant Therapeutic Antibodies and Proteins Market
      • By Drug Class:
        • Plasma Protein
        • Growth Factors
        • Fusion Proteins
        • Monoclonal Antibodies
        • Hormones
        • Enzyme
        • Coagulation Factors
        • Others
      • By Application:
        • Oncology
        • Hematology
        • Immunology
        • Endocrinology
        • Infectious Disease
        • Cardiovascular Diseases
        • Others
      • By Country:
        • U.S.
        • Canada
    • Latin America Recombinant Therapeutic Antibodies and Proteins Market
      • By Drug Class:
        • Plasma Protein
        • Growth Factors
        • Fusion Proteins
        • Monoclonal Antibodies
        • Hormones
        • Enzyme
        • Coagulation Factors
        • Others
      • By Application:
        • Oncology
        • Hematology
        • Immunology
        • Endocrinology
        • Infectious Disease
        • Cardiovascular Diseases
        • Others
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe Recombinant Therapeutic Antibodies and Proteins Market
      • By Drug Class:
        • Plasma Protein
        • Growth Factors
        • Fusion Proteins
        • Monoclonal Antibodies
        • Hormones
        • Enzyme
        • Coagulation Factors
        • Others
      • By Application:
        • Oncology
        • Hematology
        • Immunology
        • Endocrinology
        • Infectious Disease
        • Cardiovascular Diseases
        • Others
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific Recombinant Therapeutic Antibodies and Proteins Market
      • By Drug Class:
        • Plasma Protein
        • Growth Factors
        • Fusion Proteins
        • Monoclonal Antibodies
        • Hormones
        • Enzyme
        • Coagulation Factors
        • Others
      • By Application:
        • Oncology
        • Hematology
        • Immunology
        • Endocrinology
        • Infectious Disease
        • Cardiovascular Diseases
        • Others
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East Recombinant Therapeutic Antibodies and Proteins Market
      • By Drug Class:
        • Plasma Protein
        • Growth Factors
        • Fusion Proteins
        • Monoclonal Antibodies
        • Hormones
        • Enzyme
        • Coagulation Factors
        • Others
      • By Application:
        • Oncology
        • Hematology
        • Immunology
        • Endocrinology
        • Infectious Disease
        • Cardiovascular Diseases
        • Others
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa Recombinant Therapeutic Antibodies and Proteins Market
      • By Drug Class:
        • Plasma Protein
        • Growth Factors
        • Fusion Proteins
        • Monoclonal Antibodies
        • Hormones
        • Enzyme
        • Coagulation Factors
        • Others
      • By Application:
        • Oncology
        • Hematology
        • Immunology
        • Endocrinology
        • Infectious Disease
        • Cardiovascular Diseases
        • Others
      • By Country:
        • North Africa
        • South Africa
        • Central Africa
  • Company Profiles
    • Abbott Laboratories*
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Overview
      • Market Strategy
    • Amgen Inc.
    • Biogen Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche
    • Johnson and Johnson
    • Merck & Co.
    • Novo Nordisk
    • Pfizer, Inc.
    • Sanofi S.A.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Application
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Market Trends
    • Pipeline Analysis
    • Drug Development Challenges
    • New Market Entrants
    • Regulatory Scenario
    • PEST Analysis
    • Porter’s Analysis
  4. Global Recombinant Therapeutic Antibodies and Proteins Market, By Drug Class, 2016 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017–2026
      • Segment Trends
    • Plasma Protein
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Growth Factors
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Fusion Proteins
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Monoclonal Antibodies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Hormones
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Enzyme
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Coagulation Factors
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
  5. Global Recombinant Therapeutic Antibodies and Proteins Market, Application, 2016 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017–2026
      • Segment Trends
    • Oncology
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Hematology
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Immunology
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Endocrinology
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Infectious Disease
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Cardiovascular Disease
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
  6. Global Recombinant Therapeutic Antibodies and Proteins Market, By Region, 2016 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2026
      • Regional Trends
    • North America
      • Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • Germany
        • U.K.
        • France        
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • South Africa
        • Central Africa
        • North Africa
  7. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Abbott*
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategy
      • Amgen Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategy
      • Biogen Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategy
      • Eli Lilly and Company
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategy
      • F. Hoffmann-La Roche
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategy
      • Johnson and Johnson
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategy
      • Merck & Co.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategy
      • Novo Nordisk
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategy
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategy
      • Sanofi S.A.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategy
    • Analyst Views
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 22 market data tables and 27 figures on "Recombinant Therapeutic Antibodies and Proteins Market - Global forecast to 2026”.

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.